Press Room

AAPS 2016

Start
Sunday, November 13, 2016 - 00:00
End
Thursday, November 17, 2016 - 00:00
Location: Denver, United States
Booth Number: 1627
spray drying pharmaceutical industry USA | Hovione

Hovione will be present at the 2016 AAPS Annual Meeting in the Colorado Convention Center in Denver.

A set of seven (7) posters will be exhibited in the poster session. If you are attending AAPS, look for Hovione in the poster session and meet with one of our experts.

 

HOVIONE POSTERS

Aerodynamic Performance of DPIs versus Process Efficiency: A Necessary Compromise
Filipa M. Maia, Maria Palha, Isabel S. Lopes, Filipe Neves

 

Watch Poster Video at AAPS by Márcio Temtem:

 

Innovative Spray Drying Process for Microencapsulation of Dexamethasone for Controlled Ocular Release
Filipa M. Maia1 , Maria Paiva1 , R. Yamamoto2 , T. Cavanagh2 , Filipe Neves1
1 Hovione PharmaScience S.A., 2 Precision Ocular Ltd.

Bulk Properties Impact on the Performance of Amorphous Solid Dispersions 
Iris Duarte, Rui Ferreira, João Vicente

The Impact of Reprocessing on Typical Physicochemical Attributes and Particle Properties of Spray Dried Kollidon® VA64
Rui Ferreira, Iris Duarte, Márcio Temtem

Particle Engineering through Solvent Precipitation: Batch vs Continuous Operation 
Tiago Porfirio, Iris Duarte, João Vicente

Compaction Simulation of an Amorphous Spray Dried Dispersion
João Henriques, Márcio Temtem, Conrad Winters

Modeling Droplet Dynamic and Thermal Profile of Spray Congealing Technology
Inês Matos, Hugo Lisboa, João Henriques, Márcio Temtem

 

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at AAPS.

Schedule a meeting button | Hovione

 

Our colleague, Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

       

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024